Literature DB >> 107960

An artificial 'haemophilic' plasma for one-stage factor-VIII assay.

V Chantarangkul, G I Ingram, M B Thorn, S C Darby.   

Abstract

An 'artificial' plasma for one-stage factor-VIII assays is made by incubating human plasma with EDTA, to destroy factor VIII, and afterwards removing the anticoagulant by dialysis. Bovine factor V is then added to a given level. In the assay, contact activation is controlled by adding contact product. It was confirmed that factor-VIII activity was destroyed and that the EDTA was freely dialysable. The fibrinogen in the treated plasma clotted normally with thrombin. Likely variation in the factor-V activity was found not to be critical. The concentration of fibrinogen and other factors was adequate. Variation between batches was small. The artificial plasma yielded assay results closely comparable to haemophilic plasma in samples with factor-VIII activities in the range 0.01--20.0 iu/ml; the mean results in the artificial system were estimated to be 0.997 x those in haemophilic plasma, with a 95% confidence interval of 0.901--1.103. Biological variability in individual assays was smaller in the artificial system than when haemophilic plasma was used. Instability at the bench was more often detected in the artificial system than in haemophilic plasma assays, but the effect was eliminated from the results by obtaining duplicated readings in a balanced order.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 107960     DOI: 10.1111/j.1365-2141.1978.tb05818.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Artificial factor VIII deficient plasma: preparation using monoclonal antibodies and its use in one stage coagulation assays.

Authors:  V S Hornsey; Y G Waterston; C V Prowse
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

2.  Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.

Authors:  A G Benny; P A Ockelford; A S Johns; R H Scott; D G Woodfield; E W Berry
Journal:  J Clin Pathol       Date:  1988-09       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.